0.16
+0.57%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MDxHealth
Its shares trade under the ticker MDXH. It has been listed since 26 June 2006. In the fiscal year to 31 December 2025, it reported revenue of $107.9m and a net loss of $33.5m. At that date it held total assets of $148.0m and shareholders' equity of −$12.1m.
MDxHealth SA is a BE-based company operating in Biotechnology industry. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jun 2006
- Employees
- 364
- Website
- mdxhealth.com ↗
- Head office
- CAP BUSINESS CENTER, HERSTAL, C9, 00000
- Incorporated in
- C9
- Classification
- Services-Medical Laboratories
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Mark ShaffarNon-Executive Independent Chairman of the Board€20,000
- Mr. Michael McGarrityChief Executive Officer, Director, since 2019
- Mr. Ron KalfusChief Financial Officer
- Mr. Joseph SolleeExecutive Vice President, Chief Compliance Officer, General Counsel
- Mr. Christopher ThibodeauExecutive Vice President & U.S. Chief Operations Officer
- Mr. John BellanoChief Commercial Officer
- Mr. Michael HolderDirector
- Dr. Sanford SiegelDirector
- Mr. Rudi MarienNon-Executive Director
- Mme. Ruth DevenynsNon-Executive Independent Director€30,000
- Mr. Walter NarajowskiNon-Executive Independent Director€28,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MDxHealth SA employs 364 employees in Biotechnology sector with headquarters in Herstal, Belgium.
- MDxHealth SA provides molecular diagnostic tests like ConfirmMDx for Prostate Cancer and SelectMDx for Prostate Cancer.
- MDxHealth SA operates laboratories in Nijmegen, Netherlands, and Irvine, United States for global service delivery.
Weaknesses
- MDxHealth SA has 258 full-time employees which is lower than the industry average in Biotechnology.
- MDxHealth SA's IPO was on 26 June 2006, a long time ago with limited recent market activity.
- MDxHealth SA's corporate operations are based in Herstal, Belgium, which may limit international expansion.
Opportunities
- MDxHealth SA can expand its molecular diagnostic tests to new cancer types like Glioblastoma and Bladder Cancer.
- MDxHealth SA can leverage its proprietary genetic and epigenetic technologies for new market segments.
- MDxHealth SA can grow its presence in the United States with operations in Irvine, California.
Threats
- MDxHealth SA faces competition from other Biotechnology companies in the Health Care sector.
- MDxHealth SA's laboratory operations in Nijmegen, Netherlands, may face regulatory challenges in Europe.
- MDxHealth SA's reliance on molecular diagnostic tests for cancer may be affected by new medical guidelines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.